FY2025 · ended Dec 31, 2025 · Revenue $570,000, +13.8% YoY · Filed Feb 27, 2026
Yarrow Bioscience, Inc. (YARW) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $570,000 and a net loss of $26.5 million. Free cash flow was -$33.1 million. As of Jun 30, 2026 it held $22.9 million in cash and investments and $0 in total debt.
Revenue (TTM)
$482,000
+1.3% vs year-ago TTM
Net income (TTM)
$-18.71M
+51.5% vs year-ago TTM
Operating cash flow (TTM)
$-16.93M
+57.4% vs year-ago TTM
Free cash flow
$-33.12M
+2.8% vs prior year
EPS (TTM)
$-0.44
+75.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
33.32M
+119.1% vs prior year
Net cash
$22.93M
as of Jun 30, 2026
Operating margin
-4134.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- YARW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1566044
- Former names
- VYNE Therapeutics Inc. (until Jul 24, 2026); Menlo Therapeutics Inc. (until Sep 2, 2020); Menlo Therapeutics, Inc. (until Jan 31, 2018); Tigercat Pharma, Inc. (until Jan 7, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 |
| Operating income | -$29.7M | -$43.6M | -$29.3M | -$34.3M | -$38.9M |
| Net income | -$26.5M | -$39.8M | -$28.5M | -$23.2M | -$73.3M |
| Diluted EPS | -$0.62 | -$0.93 | -$2.78 | -$7.28 | -$25.64 |
| Operating cash flow | -$33.1M | -$34.0M | -$25.3M | -$29.2M | -$56.4M |
| Free cash flow | -$33.1M | -$34.1M | — | — | -$56.4M |
| Total assets | $30.2M | $66.9M | $97.7M | $40.8M | $67.0M |
| Total liabilities | $2.4M | $14.8M | $8.9M | $9.3M | $18.4M |
| Stockholders' equity | $27.8M | $52.1M | $88.7M | $31.2M | $48.6M |
| Cash and investments | $29.0M | $61.5M | $93.3M | $30.9M | $42.2M |
| Total debt | $0 | $99,000 | $214,000 | $0 | $349,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 14, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
| 8-K/A |
Amended current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Jul 24, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 30, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Results of operations, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 28, 2026 | Jul 24, 2026 |
All 682 Yarrow Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.